The drug will be co-promoted by Espirt Pharma and Indevus Pharmaceuticals.Niche pharmaceutical company Esprit Pharma, based in East Brunswick, has acquired U.S. marketing rights to Sanctura, a ...
SANCTURA and SANCTURA XR possess a quaternary ammonium structure that may be instrumental in the low incidence of CNS side-effects. At therapeutic concentrations in vitro, SANCTURA does not interact ...
LEXINGTON, Mass., Sept. 19 IndevusPharmaceuticals, Inc. (Nasdaq: IDEV) today announced that Allergan, Inc.(NYSE: AGN), through its acquisition of Esprit Pharma, has obtained the UnitedStates rights to ...
Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR ® (trospium chloride extended release capsules), ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR ® ...
Small drug company Indevus (NASDAQ:IDEV) had the good fortune of a drug approval this year for Sanctura, which treats overactive bladder, or increased urinary frequency or urges to urinate. The leader ...
LEXINGTON, Mass., Aug. 6 -- Indevus Pharmaceuticals, Inc. today announced that SANCTURA® XR (trospium chloride extended release capsules) has been approved by the U.S. Food and Drug Administration ...
The drug company puts troubled history behind it with the launch of Sanctura. But the past is the past and Indevus has come a long way in recent years. While you may not know it from the lack of ...
Each company will obtain $7 million upfront and $2 million in commercialization-based payments. Indevus Pharmaceuticals and Rottapharm Madaus granted Allergan’s Canadian affiliate rights to market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results